Skip to main content

Table 1 Clinical and molecular characteristics of TCGA AML patients according to the mutation and/or copy number variation status of genes encoding m6A regulatory enzymes

From: Genetic alterations of m6A regulators predict poorer survival in acute myeloid leukemia

 

Mutation and/or CNV

CNV onlya

Mutation

Yes (n = 23)

No (n = 168)

P

Yes (n = 18)

No (n = 168)

P

Yes (n = 5)

No (n = 186)

P

Age

  

0.083

  

0.193

  

0.205

Median (range)

65 (18–81)

57 (21–88)

 

62.5 (18–81)

57 (21–88)

 

65 (45–76)

57.5 (18–88)

 

Sex, no. (%)

  

0.123

  

0.321

  

0.376

Male

16 (8.4)

87 (45.5)

 

12 (6.5)

87 (46.8)

 

4 (2.1)

99 (51.8)

 

Female

7 (3.7)

81 (42.4)

 

6 (3.2)

81 (43.5)

 

1 (0.5)

87 (45.5)

 

BM blast

  

0.072

  

0.038

  

0.915

Median % (range)

60 (30–97)

73 (30–100)

 

54 (30–97)

73 (30–100)

 

75 (33–90)

72 (30–100)

 

WBC, ×103/mm3

  

0.084

  

0.047

  

0.889

Median (range)

5.4 (0.7–202.7)

17.5 (0.4–298.4)

 

5.2 (2.3–101.3)

17.45(0.4–298.4)

 

14.5 (2.3–101.3)

15.6 (0.4–298.4)

 

Cytogenetic risk, no. (%)

  

<0.0001

  

<0.0001

  

0.483

Favorable

0 (0)

37 (19.4)

 

0 (0)

37 (19.9)

 

0 (0)

37 (19.4)

 

Intermediate

4 (2.1)

105 (55)

 

1 (0.5)

105 (56.5)

 

3 (1.6)

106 (55.5)

 

Unfavorable

19 (9.9)

21 (11)

 

17 (9.1)

21 (11.3)

 

2 (1)

38 (19.9)

 

Missing data

0 (0)

5 (2.6)

 

0 (0)

5 (2.6)

 

0 (0)

5 (2.6)

 

Mutation, no./total no. (%)

FLT3

1/23 (4.3)

53/168 (31.5)

0.005

0/18 (0)

53/168 (31.5)

0.002

1/5 (20)

53/186 (28.4)

1.000

NPM1

1/23 (4.3)

51/168 (30)

0.006

0/18 (0)

51/168 (30.3)

0.004

1/5 (20)

51/186 (27.4)

1.000

DNMT3A

4/23 (17.4)

43/168 (25.6)

0.453

2/18 (11.1)

43/168 (25.6)

0.249

2/5 (40)

45/186 (24.2)

0.598

IDH1 or IDH2

1/23 (4.3)

34/168 (20.2)

0.084

0/18 (0)

34/168 (20.2)

0.048

1/5 (20)

34/186 (18.3)

1.000

NRAS or KRAS

3/23 (13)

20/168 (11.9)

0.744

3/18 (16.7)

20/168 (11.9)

0.471

0/5 (0)

23/186 (12.4)

1.000

RUNX1

2/23 (8.7)

17/168 (10.1)

1.000

0/18 (0)

17/168 (10.1)

0.380

2/5 (40)

17/186 (9.1)

0.078

TET2

1/23 (4.3)

15/168 (8.9)

0.698

1/18(5.6)

15/168 (8.9)

1.000

0/5 (0)

16/186 (8.6)

1.000

TP53

15/23 (65.2)

1/168 (0.6)

<0.0001

13/18 (72.2)

1/168 (0.6)

<0.0001

2/5 (40)

14/186 (7.5)

0.057

CEBPA

2/23 (8.7)

10/168 (6.0)

0.641

2/18 (11.1)

10/168 (6.0)

0.327

0/5 (0)

12/186 (6.5)

1.000

WT1

0/23 (0)

12/168 (7.1)

0.366

0/18 (0)

12/168 (7.1)

0.610

0/5 (0)

12/186 (6.5)

1.000

PTPN11

2/23 (8.7)

6/168 (3.6)

0.248

2/18 (11.1)

6/168 (3.6)

0.175

0/5 (0)

8/186 (4.3)

1.000

KIT

1/23 (4.3)

6/168 (3.6)

0.599

0/18 (20)

6/168 (3.6)

1.000

1/5 (20)

6/186 (3.2)

0.172

  1. Significant P values are in bold
  2. CNV copy number variation, BM bone marrow, WBC white blood cell
  3. aExcluding samples with m6A regulatory gene mutations